<DOC>
	<DOC>NCT01149018</DOC>
	<brief_summary>The objective of the study is to evaluate the effectiveness of oral tetrahydrocannabinol in patients suffering from Fibromyalgia</brief_summary>
	<brief_title>Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Adult (&gt;18y.o) Patient with Fibromyalgia, diagnosed by ACR criteria Children &lt; 18 years old Patients with following psychiatric disorders: Psychosis or history of acute psychosis Schizophrenia Bipolar disorder Patients smoking marijuana, using hashish or any other form of cannabis. Patients with history of drug abuse or illicit drug use Patients receiving chronic treatment with strong opioids (Morphine, Oxycodone, Fentanyl, Methadone, Hydromorphone, Buprenorphine, Pethidine). Weak opioids as Tramadol or Propoxyphene will be allowed. Pregnant patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Fibromyalgia</keyword>
	<keyword>Tetrahydrocannabinol</keyword>
	<keyword>Chronic Widespread Pain</keyword>
</DOC>